Compare · BHVN vs LLY
BHVN vs LLY
Side-by-side comparison of Biohaven Ltd. (BHVN) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BHVN and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 682.5x BHVN ($1.73B).
- Over the past year, BHVN is down 38.4% and LLY is up 55.4% - LLY leads by 93.8 points.
- LLY has been more active in the news (19 items in the past 4 weeks vs 2 for BHVN).
- Both have 25 recent analyst ratings on file.
- Company
- Biohaven Ltd.
- Eli Lilly and Company
- Price
- $10.79-5.72%
- $1257.32+0.45%
- Market cap
- $1.73B
- $1.18T
- 1M return
- -22.28%
- +9.10%
- 1Y return
- -38.42%
- +55.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 2
- 19
- Recent ratings
- 25
- 25
Biohaven Ltd.
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest BHVN
- SEC Form 8-K filed by Biohaven Ltd.
- Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
- SEC Form 4 filed by SVP, Clinical Operations Gentile Kimberly
- Biohaven Ltd. filed SEC Form 8-K: Other Events
- Biohaven downgraded by RBC Capital Mkts with a new price target
- Biohaven Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
- Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
- New insider Yetimoglu John claimed ownership of 6,250,000 shares (SEC Form 3)
- SEC Form SCHEDULE 13G filed by Biohaven Ltd.
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease